03 January 2023: Original Paper
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and Relapse Settings: A Retrospective Study in China
Jing Liu 1BCDEF* , Haitao Wang 1BCDF* , Xiaohong Li 1B , Yamei Wu 1B , Yuanyuan Ma 1B , Zhenyang Gu 1B , Fei Li 1B , Meng Li 1BD , Jiayuan Guo 2B , Yu Zhao 1B , Quanshun Wang 1B , Jian Bo 1B , Wenrong Huang 1B , Liping Dou 1BD , Yuanbo Liu 3AEF , Daihong Liu 1BD , Xiaoxiong Wu 1ADF* , Chunji Gao 1ADEFG*DOI: 10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
Table 3 ASCT as salvage treatment for relapsed/refractory patients with PCNSL.
| Sex/age | Patient | ECOG | Number of recurrences before ASCT | Conditioning regimen | Pre-ASCT | Post-ASCT | Timing of WBRT | Neutrophil/platelet engraftment time (days) | |
|---|---|---|---|---|---|---|---|---|---|
| M/61 | 11 | 2 | 1 | TBC-like | CR2 | CR | – | 10/12 | |
| M/56 | 12 | 2 | 1 | Modified TBC | CR2 | CR | – | 13/15 | |
| M/50 | 13 | 1 | 1 | Modified TBC | CR2 | CR | Before ASCT | 13/13 | |
| M/22 | 14 | 0 | 1 | Modified TBC | CR2 | CR | – | 31/35 | |
| M/44 | 15 | 3 | 2 | Modified TBC | PR | PR | Before ASCT | 15/28 | |
| F/49 | 16 | 2 | 4 | Modified TBC | PR | CR | Before ASCT | 16/50 | |
| M/59 | 17 | 3 | 3 | Modified TBC | CRu3 | PD | – | 15/− | |
| M/47 | 18 | 3 | 0 | Modified TBC | PR | CRu | Before ASCT | 13/13 | |
| F/53 | 19 | 1 | 0 | Modified TBC | CRu | CR | Before ASCT | 12/17 | |
| M/40 | 20 | 2 | 1 | TBC-like | CR | CR | Before ASCT | 19/108 | |
| M/61 | 11 | Haematologic toxicities, fever, hypokalaemia, gastrointestinal toxicities | – | 15.0 | 15.0 | A Wo D | |||
| M/56 | 12 | Haematologic toxicities, fever, rashgastrointestinal toxicities, mucositis | – | 9.5 | 9.5 | A Wo D | |||
| M/50 | 13 | Haematologic toxicities, fever, gastrointestinal toxicities | Leukoencephalopathy | 27.0 | 27.0 | A Wo D | |||
| M/22 | 14 | Haematologic toxicities, haemorrhagic cystitis | – | 33.2 | 33.2 | A Wo D | |||
| M/44 | 15 | Haematologic toxicities, gastrointestinal toxicities | Alalia, Unresponsive | 4.5 | 4.5 | TRD | |||
| F/49 | 16 | Haematologic toxicities, gastrointestinal toxicities, infection, mucositis | – | 12.7 | 12.7 | A Wo D | |||
| M/59 | 17 | Haematologic toxicities, gastrointestinal toxicities, pneumonia, encephalitis | – | 0.53 | 0.53 | TRD | |||
| M/47 | 18 | Haematologic toxicities, gastrointestinal toxicities, infection, hepatotoxicity | Alalia | 19.2 | 23.9 | DOD | |||
| F/53 | 19 | Haematologic toxicities, gastrointestinal toxicities, pneumonia | – | 1.8 | 1.8 | A Wo D | |||
| M/40 | 20 | Haematologic toxicities, gastrointestinal toxicities, infection, rash, hypokalaemia, mucositis | – | 7.7 | 7.7 | A Wo D | |||
| TBC – thiotepa + busulfan + cyclophosphamide; Modified TBC – TBC + cladribine + etoposide + cytarabine; CR – complete remission; Cru – unconfirmed CR; HDC – high-dose chemotherapy; PFS – progression-free survival; OS – overall survival; A Wo D – alive without disease; DOD – dead of disease; TRD – treatment-related death. OS1 and PFS1 were measured from the day of transplantation. | |||||||||